SCLX stock icon

Scilex Holding

0.9714 USD
+0.0111
1.16%
At close Nov 1, 4:00 PM EDT
After hours
0.9900
+0.0186
1.91%
1 day
1.16%
5 days
4.12%
1 month
9.27%
3 months
-35.24%
6 months
13.53%
Year to date
-52.38%
1 year
-46.33%
5 years
-89.61%
 

About: Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Employees: 113

0
Funds holding %
of 6,759 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

427% more call options, than puts

Call options by funds: $237K | Put options by funds: $45K

70% more capital invested

Capital invested by funds: $45.5M [Q1] → $77.2M (+$31.7M) [Q2]

4.88% more ownership

Funds ownership: 17.21% [Q1] → 22.08% (+4.88%) [Q2]

11% less funds holding

Funds holding: 100 [Q1] → 89 (-11) [Q2]

28% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 18

44% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 25

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$7
621%
upside
Avg. target
$10.50
981%
upside
High target
$14
1,341%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Raghuram Selvaraju
47% 1-year accuracy
114 / 245 met price target
621%upside
$7
Buy
Reiterated
21 Oct 2024
Alliance Global Partners
James Molloy
13% 1-year accuracy
1 / 8 met price target
1,341%upside
$14
Buy
Initiated
16 Oct 2024

Financial journalist opinion

Based on 8 articles about SCLX published over the past 30 days

Neutral
GlobeNewsWire
2 months ago
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value of Semnur of $2.5 Billion
PALO ALTO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, and Denali Capital Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company (Nasdaq: DECA, the “SPAC”), today announced the signing of an agreement and plan of merger for a proposed business combination, by and among Semnur, the SPAC and Denali Merger Sub Inc., a Delaware Corporation and wholly owned subsidiary of the SPAC, which provides for a pre-transaction equity value of Semnur at $2.5 billion.   Prior to the closing of the transaction, the SPAC will be redomesticated as a Delaware corporation. Upon closing of the transaction, the combined company (the “Combined Company”) will be renamed Semnur Pharmaceuticals, Inc., and its common stock and warrants are expected to be listed on Nasdaq under the ticker symbols “SMNR” and “SMNRW”, respectively. The boards of directors of each of the SPAC, Semnur and Scilex have unanimously approved the proposed transaction. The closing of the transaction, which is expected to occur by the first quarter of 2025, is subject to the approval of the SPAC's shareholders, any applicable regulatory approval, and the satisfaction or waiver of certain other closing conditions.
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value of Semnur of $2.5 Billion
Charts implemented using Lightweight Charts™